HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $9 price target.
Stocks · News reference
LifeMD shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 sales guidance. Also, the company issued Q3 sales guidance below estimates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
B. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $8
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $8.